FHA
CMPX icon

Flagship Harbor Advisors’s Compass Therapeutics CMPX Stock Holding History

Flagship Harbor Advisors’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,000
Closed -$32.2K – 980
2025
Q4 		$32.2K Buy
+6,000
New +$27.7K ﹤0.01% 1188
2023
Q4 		– Sell
-11,000
Closed -$21.7K – 630
2023
Q3 		$21.7K Hold
11,000
– – ﹤0.01% 603
2023
Q2 		$35K Sell
11,000
-500
-4% -$1.57K ﹤0.01% 611
2023
Q1 		$37.6K Hold
11,500
– – ﹤0.01% 609
2022
Q4 		$57.8K Sell
11,500
-2,500
-18% -$9.97K 0.01% 593
2022
Q3 		$32K Hold
14,000
– – ﹤0.01% 579
2022
Q2 		$37K Buy
+14,000
New +$30.4K ﹤0.01% 587

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Flagship Harbor Advisors's CMPX Position: Q1 2026 in Review

Flagship Harbor Advisors sold out of Compass Therapeutics (CMPX) in Q1 2026, closing a stake of 6,000 shares — an estimated $32.2K sold.

Flagship Harbor Advisors first reported a position in CMPX in Q2 2022 and held it in 7 quarters. The position peaked at $57.8K in Q4 2022. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • Flagship Harbor Advisors reported no remaining Compass Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Flagship Harbor Advisors sold 6,000 Compass Therapeutics shares in Q1 2026, an estimated $32.2K.
  • Flagship Harbor Advisors first reported a position in Compass Therapeutics in Q2 2022 and held it in 7 quarters.
  • Flagship Harbor Advisors's Compass Therapeutics position peaked at $57.8K in Q4 2022.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on Flagship Harbor Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.